Healthcare Services Australia

Australia Biosimilar Development Services Market Analysis, 2024–2034

Australia Biosimilar Development Services Market Industry Trends and Forecast to 2034: Segmented by (Service, Molecule, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $30.5 Mn Estimated value
Estimate 2025 $34.5 Mn 1.4% of the global market
Projected 2034 $105.2 Mn 205.2% Adds $70.7 Mn over 9 forecast years
CAGR 2025–2034 13.2% Faster than 75% of 107 Healthcare Services markets here
Key players 5
  • Australia is 1.37% of the global market.
  • In APAC, the largest is China at $183.5 Mn.
  • Fastest growing: India at 14.8% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$70.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Biosimilar Development Services Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $30.5 Mn — —
2025 (base) $34.5 Mn +$4.0 Mn —
2026 (forecast) $39.0 Mn +$4.6 Mn +13.2%
2027 (forecast) $44.2 Mn +$5.2 Mn +28.1%
2028 (forecast) $50.0 Mn +$5.8 Mn +45.1%
2029 (forecast) $56.6 Mn +$6.6 Mn +64.2%
2030 (forecast) $64.1 Mn +$7.5 Mn +85.9%
2031 (forecast) $72.5 Mn +$8.5 Mn +110.4%
2032 (forecast) $82.1 Mn +$9.6 Mn +138.2%
2033 (forecast) $92.9 Mn +$10.8 Mn +169.6%
2034 (forecast) $105.2 Mn +$12.3 Mn +205.2%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $2.51 Bn
  2. North America $1.05 Bn
  3. US $942.0 Mn
  4. APAC $546.1 Mn
  5. Europe $419.2 Mn
  6. Canada $197.1 Mn
  7. China $183.5 Mn
  8. Japan $172.9 Mn
  9. Middle East $114.9 Mn
  10. Latin America $99.5 Mn
  11. Germany $84.8 Mn
  12. France $75.9 Mn
  13. Italy $67.4 Mn
  14. UK $60.9 Mn
  15. Brazil $59.7 Mn
  16. Spain $51.9 Mn
  17. India $48.8 Mn
  18. Ecuador $43.1 Mn
  19. Africa $38.9 Mn
  20. Saudi Arabia $38.1 Mn
  21. Mexico $37.0 Mn
  22. Australia (this report) $34.5 Mn
  23. Russia $30.9 Mn
  24. New Zealand $29.8 Mn
  25. South Africa $19.1 Mn
  26. UAE $12.8 Mn
  27. Philippines $6.4 Mn
  28. Egypt $6.3 Mn
  29. Hong Kong $4.2 Mn
  30. Malaysia $3.9 Mn
  31. Thailand $3.4 Mn
  32. Singapore $3.1 Mn
  33. Kenya $1.9 Mn

The Australia Biosimilar Development Services Market Analysis Executive Summary

Biosimilar development services help companies develop, test and gain approval for biosimilar medicines.

Key segments of the biosimilar Development Services market include service (Analytical Characterization, Clinical Studies and Manufacturing) and molecule (Antibodies, Insulins and Others).

Australia Biosimilar Development Services Market Dynamics

Market Growth Drivers

Growing drug pipelines, more complex biologics, cost pressure on drug makers and the need for speed are driving the biosimilar Development Services market. Many companies now outsource work they used to do in-house.

Opportunity

Advanced therapies, AI-driven operations and expansion in India, China and Southeast Asia give the biosimilar Development Services market room to grow.

Market Restraints

Capacity shortages, strict quality rules, data security concerns and pricing pressure hold back the biosimilar Development Services market.

Competitive Landscape for Biosimilar Development Services Market in Australia

The biosimilar Development Services market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Biosimilar Development Services Market in Australia

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how biosimilar Development Services services are delivered and paid for in Australia. Government health programs and insurance coverage are key to access.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Biosimilar Development Services right now, from free public sources.

Latest research 121 papers since 2021 (worldwide)

  1. Biosimilar Development Considerations for Therapeutic Proteins With Limited Systemic Exposure: A Landscape Analysis and Pathway Evaluation. Clinical pharmacology and therapeutics, 2026
  2. Analytical Characterization for Similarity Assessment Between Biosimilar SB16 and Denosumab Reference Product Using State-of-the-Art Analytical Method. Drugs in R&D, 2026
  3. Analytical Advances and Evidence-Proportionate Biosimilar Development. Therapeutic innovation & regulatory science, 2026
  4. Bioanalytical assays for clinical similarity assessment of biotherapeutics: evolving platforms and regulatory considerations. Bioanalysis, 2026
  5. Proportionate evidence in biosimilar development: when a comparative efficacy study can still change the regulatory conclusion. npj drug discovery, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Biosimilar Development Services in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How much research is published on Biosimilar Development Services?
PubMed lists 121 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Biosimilar Development Services in Australia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Healthcare Services reports in Australia

See all
Same topic, other categories

Related on drug development and manufacturing and biologics and biosimilars

See the topic